Showing 4901-4910 of 21485 results for "".
- Two New SkinMedica Products Target Skin Hydration and Barrier Supporthttps://reachmd.com/news/two-new-skinmedica-products-target-skin-hydration-and-barrier-support/2488404/SkinMedica has expanded its skin barrier and hydration portfolio with the launch of Barrier Calming Cream and HA5 Hydra Collagen Facial Mist with Vegan Collagen, according to an announcement from the company. New SkinMedica Products for Hydration and Skin Barrier Support Barrier
- Levofloxacin Prophylaxis Failure Tied to Resistance and PK/PDhttps://reachmd.com/news/levofloxacin-prophylaxis-failure-tied-to-resistance-and-pkpd/2488380/Key Takeaways In this prospective matched case–control study, investigators analyzed 60 prophylaxis-failure episodes and 60 matched prophylaxis-success episodes; the design does not establish the overall failure rate during levofloxacin prophylaxis, and profound neutropenia w
- Four DENV Lineages Drove Espírito Santo Dengue Surgehttps://reachmd.com/news/four-denv-lineages-drove-espirito-santo-dengue-surge/2488383/Key Takeaways In Espírito Santo, Brazil, 127,070 confirmed dengue cases were reported in 2023 and 131,170 in 2024 during back-to-back epidemic years. Warning signs or severe dengue were reported in 2.8% of confirmed cases in 2023 and 2% in 2024, indicating that most
- Off-Midline Flaps Lower Recurrence in Pilonidal Surgeryhttps://reachmd.com/news/off-midline-flaps-lower-recurrence-in-pilonidal-surgery/2488368/Key Takeaways In a 2,222-patient cohort from a tertiary university hospital in Istanbul, Turkey, 5-year cumulative recurrence after surgery for primary pilonidal sinus disease was 7.9% and postoperative wound infection was 6.9%. In the study’s full results, fasciocut
- Retrobulbar Hematoma: CT Predictors of Vision Loss After Traumahttps://reachmd.com/news/retrobulbar-hematoma-ct-predictors-of-vision-loss-after-trauma/2488385/Key Takeaways The authors reported 52 retrobulbar hematoma cases among 7,671 registry patients (0.7%), although the paper inconsistently describes the denominator as head-and-neck trauma versus midface fracture cases and gives differing study dates. Cases were seen m
- PCA SKIN Launches Acne Control Prebiotic Gel Cleanserhttps://reachmd.com/news/pca-skin-launches-acne-control-prebiotic-gel-cleanser/2488391/PCA SKIN has launched Acne Control Prebiotic Gel Cleanser, a daily cleanser designed for acne-prone skin that pairs acne-fighting ingredients with technology intended to support the skin microbiome. The gel-to-lather cleanser contains 2% salicylic acid to help clear and prevent acne breako
- PrecivityAD2 APS2 Shows 91% Accuracy vs Amyloid PEThttps://reachmd.com/news/precivityad2-aps2-shows-91-accuracy-vs-amyloid-pet/2488370/Key Takeaways In an independent ADNI cohort of cognitively impaired participants, APS2 showed high concordance with amyloid PET; the authors said these findings support use in symptomatic patients evaluated in clinical care. More than half of participants had a posit
- Nomogram Predicts Parenchymal Hematoma After EVThttps://reachmd.com/news/nomogram-predicts-parenchymal-hematoma-after-evt/2488369/Key Takeaways In a single-center Chinese cohort of adults with large-core anterior circulation stroke treated with EVT, parenchymal hematoma was observed in 19.5% of patients. The final nomogram incorporated baseline NIHSS, monocytes, platelets, post-thrombectomy fas
- Enliven Therapeutics to Present Encore Data on Leukemia Drug ELVN-001 at SOHO 2026https://reachmd.com/news/enliven-therapeutics-to-present-encore-data-on-leukemia-drug-elvn-001-at-soho-2026/2488345/Key Takeaways Enliven Therapeutics will present Phase 1 data on ELVN-001, an investigational BCR::ABL1 inhibitor, at the SOHO 2026 Annual Meeting, September 9–12 in Houston, Texas. Data comes from the ongoing ENABLE trial in patients with previously treated
- PTEHL Cleared Bile Duct Stones in 80+ Patientshttps://reachmd.com/news/ptehl-cleared-bile-duct-stones-in-80-patients/2488347/Key Takeaways At a single center, patients aged 80 years and older undergoing PTEHL for intrahepatic and/or extrahepatic bile duct stones had complete clearance in 72% and near-complete clearance in 28%. Most treatment courses were completed in one session, with 96%